AMAG Pharmaceuticals (AMAG) Stock Price, News & Analysis

Company Overview

AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $13.75 to $13.75
• 50-Day Range: $13.69 to $13.75
• 52-Week Range: $4.41 to $13.80
• Volume: N/A
• Average Volume: 950,664 shs
• Market Capitalization: $477.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AMAG Stock Analysis - Frequently Asked Questions

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) issued its quarterly earnings results on Monday, May, 11th. The specialty pharmaceutical company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.27. The specialty pharmaceutical company earned $68.66 million during the quarter, compared to analysts' expectations of $64.95 million. AMAG Pharmaceuticals had a negative trailing twelve-month return on equity of 16.92% and a negative net margin of 74.93%.

What other stocks do shareholders of AMAG Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AMAG Pharmaceuticals investors own include Bristol-Myers Squibb (BMY), Palatin Technologies (PTN), Gilead Sciences (GILD), Meta Platforms (META), Bausch Health Companies (BHC), Netflix (NFLX) and Tesla (TSLA).

Company Calendar

• Last Earnings: 5/11/2020
• Today: 5/10/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AMAG
• CIK: 792977
• Web: www.amagpharma.com
• Phone: 617-498-3300
• Fax: N/A
• Employees: 440
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($6.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-466,460,000.00
• Net Margins: -74.93%
• Pretax Margin: N/A
• Return on Equity: -16.92%
• Return on Assets: -5.96%

Debt

• Debt-to-Equity Ratio: 1.13
• Current Ratio: 1.75
• Quick Ratio: 1.45

Sales & Book Value

• Annual Sales: $327.75 million
• Price / Sales: 1.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.37 per share
• Price / Book: 1.87

Miscellaneous

• Outstanding Shares: 34,725,000
• Free Float: N/A
• Market Cap: $477.47 million
• Optionable: Optionable
• Beta: 0.89